MIMS Australia has been publishing medicines information since 1963 and is the leading supplier of medicine information to Australian healthcare professionals. MIMS is known for its high level of editorial integrity and independence; a recent national survey of healthcare professionals revealed that 99.3% of respondents would recommend MIMS to a colleague.
MIMS Australia offers a range of digital products that reflect current advances in information delivery; from mobile devices (iMIMS, MIMS for Android), to online, to integrating databases into clinical and dispensing software applications.
MIMS also continues to offer the printed reference products that have supported health care professionals for nearly 60 years.
Not everyone’s needs are the same. Servicing the Australian market for over 50 years, MIMS has learnt to understand those diverse needs and has developed relevant and trusted products that give the healthcare professional the right product at the right place at the right time.
MIMS reference products together with the applications developed by our partners products are relied upon by a wide cross section of the Australian healthcare professionals. State Health Departments, Private Hospitals, aged care, medical practitioners, pharmacists, dentists, health care services and border protection authorities. All use MIMS as their reference of choice.
MIMS Australia Pty Ltd
Level 3, 53 Berry Street, North Sydney NSW 2060
Locked Bag 3000, St Leonards NSW 1590
T +61 2 9902 7700
F +61 2 9902 7701
ACN 050 695 157, ABN 68 050 695 157
About the MIMS Group
Established in 1963, the MIMS Group, together with its subsidiaries and affiliates, is the leading provider of healthcare and drug data to healthcare providers in the Asia Pacific region with approximately 2 million healthcare professional subscribers across 12 countries. In addition to its drug & resource portal, digital and print publications, MIMS has launched a career portal serving healthcare communities and a cloud-based CIS system for clinic workflow management.
Australian Medicines Handbook
Australian Medicines Handbook (AMH) was formed in 1995 under the guidance of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT), the Royal Australian College of General Practitioners (RACGP) and the Pharmaceutical Society of Australia (PSA) with the help of a government grant. The company was founded in 1996 and the first book published in 1998. These three professional organisations remain equal shareholders and have continued their involvement to the present day.
The AMHs’ philosophy is simply to use the best available evidence to support prescribing and dispensing recommendations, and its contents are intended to reflect contemporary Australian clinical practice. All content is researched and written by our experienced and suitably qualified staff editors, and external contributors, according to our editorial policy and associated procedures. A first draft is reviewed internally, and then sent for review to our Editorial Advisory Committee, and numerous external reviewers, including experts in the area, general practitioners, community and hospital pharmacists, and nurses.
Obviously, one of our core objectives is to improve the quality use of medicines in Australia. As a result of this, we continue to develop and publish books and electronic reference resources to assist in the process of quality use of medicines. We aim to do this by providing concise, accurate and easy to use information for busy practitioners, which contains the key information required for better drug treatment and prescribing choices. In order to maintain our independence, we accept no advertising, sponsorship or other forms of support from the pharmaceutical industry.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com.au
Improving Australia’s health through excellence in pharmacist care
PSA is the only Australian Government-recognised peak national professional pharmacy organisation representing all of Australia’s 34,000 pharmacists working in all sectors and across all locations. PSA is committed to supporting pharmacists in helping Australians to access quality, safe, equitable, efficient and effective healthcare.
PSA believes the expertise of pharmacists can be better utilised to address the health care needs of all Australians. PSA works to identify, unlock and advance opportunities for pharmacists to realise their full potential, to be appropriately recognised and fairly remunerated.
PSA has a strong and engaged membership base that provides high-quality health care and are the custodians for safe and effective medicine use for the Australian community. PSA leads and supports innovative and evidence-based healthcare service delivery by pharmacists.
PSA provides high-quality practitioner development and practice support to pharmacists and is the custodian of the professional practice standards and guidelines to ensure quality and integrity in the practice of pharmacy.
As Australia’s first national pharmacy body, PDL was established in 1912 by pharmacists, for pharmacists. Now over 100 years old, we are still 100% owned by our pharmacist members and are dedicated to supporting them throughout their professional life. We are a not-for-profit organisation and support over 29,000 national members in the Australian pharmacy profession, comprised mostly of hospital, clinical, research and community pharmacists, students, and interns.
At PDL, we provide member support through professional indemnity (PI) insurance that is tailored to pharmacists, covers everything in the scope of pharmacy and meets the requirements of the Pharmacy Board of Australia (Ahpra). Along with advice and procedures for risk minimisation, we aim to advance the professionalism of members through leadership, advocacy and building awareness of risk minimisation strategies.
We offer our members expertise and unbiased assistance through confidential support services, which are not punitive or judgemental. One-to-one member care and support is given via our professional officers who are themselves experienced pharmacists, so members can be assured of immediate and exceptional service.
We operate an Australia-wide, 24/7 professional incident and claims support and advice service to protect our members and to minimise patient harm. Beyond member advocacy, we support pharmacy organisations and events, research, and projects designed to enhance the profession, its standards, risk management and professional service to the Australian public.
Call 1300 854 838 for confidential, expert advice 24/7 or visit our website www.pdl.org.au
Novartis is the largest Australian medicines company, improving the lives of more than 2.8 million patients across Australia and New Zealand. From generics to gene therapy, we are committed to accelerating patient access to life saving treatments.
We are reimagining medicine by using innovative science and technology to address challenging healthcare issues and our rich pipeline has 200+ projects in development and an industry leading clinical trial footprint in Australia.
Our unbossed, curious and inspired culture unites our 700 employees, it is what unleashes the power of our people and is at the heart of the work we do each day.
Pharmacy Programs Administrator
The Pharmacy Programs Administrator is the agency responsible for administering, processing claims and making payments associated with the community pharmacy programs funded under the 7CPA. During the conference our representatives will be on hand to answer any questions you may have about our services and listen to your feedback.
QUMulus® is a cloud-database software program that has been developed by pharmacists for pharmacists to assist in the provision of extensive quality medication-related benchmarking services for the residential sector. Once-off audits are time-consuming and limited in their scope. In contrast QUMulus® provides analyses of medication usage patterns of a facility compared to others within their organisation, state or Australia-wide, as well as trend analyses within a facility over time.
Another feature which has proved to be extremely popular is individualised educational Medication Guides for use by care staff, residents or their nominated responsible person. These are also valued by recipients of HMR services.
Residential care facilities frequently find it onerous to meet their obligations in reporting Quality Indicators – problem solved when their contracted pharmacist uses QUMulus®. Furthermore, benchmarking reports through QUMulus® identify areas of concern, creating opportunities for pharmacists to formulate recommendations for further assessment and improvement in standards of practice of an organisation.
For further information about incorporating quality benchmarking and medication-related educational activities into your service contact Robyn Saunders at email@example.com